Bortezomib Shows Promise as New Mesothelioma Treatment
A drug called Bortezomib can help treat malignant mesothelioma when given directly into the area affected by the cancer. This interesting finding comes from a team of scientists from Italy. They tested Bortexomib on mesothelioma cells to find out if it can stop cancer cell growth. New Research for New Treatments Malignant mesothelioma is a rare cancer caused by asbestos exposure. It develops from the thin layer of tissue that covers many of the body’s internal organs, like the lungs and abdominal cavity. The treatment options for malignant mesothelioma are limited. Conventional treatments for mesothelioma consist of chemotherapy, surgery, and sometimes radiation therapy. Even with treatment, the prognosis for mesothelioma is not good. The median survival rate of patients with … Continue reading Bortezomib Shows Promise as New Mesothelioma Treatment
Mesothelioma Patients and Alternative Treatment
A study from Stanford University describes two mesothelioma patients who experienced an improvement in their condition without clinical treatment. This is a rare occurrence for patients with mesothelioma, even with the usual treatment. Mesothelioma is an aggressive cancer that grows in the lining of organs. This usually happens in the lungs or abdomen. It can also occur in the testis and the heart. Mesothelioma is caused by exposure to asbestos and can be hard to treat. Multimodal treatment is a common option because it involves more than one type of treatment. These are usually chemotherapy, radiation, and surgery. These types of treatments can be very hard on the body. Patients who are already frail when they arrive at the hospital … Continue reading Mesothelioma Patients and Alternative Treatment
Mesothelioma Needs a Multidisciplinary Team
Mesothelioma treatment may be best managed by a multidisciplinary team of doctors and specialized surgeons. Mesothelioma is a rare cancer that is caused by exposure to asbestos. Asbestos can be found in thousands of industrial and consumer products. People who are exposed to asbestos may not experience symptoms of mesothelioma for decades. Multimodal therapy may give patients the best odds of surviving mesothelioma. Multimodal therapy often includes surgery, chemotherapy, and radiation. Yet even when combined, these therapies achieve only limited success. The 5-year survival rate of patients with mesothelioma is less than 20%. The National Comprehensive Cancer Network recommends that patients with mesothelioma be treated by a multidisciplinary team of doctors. A multidisciplinary team includes doctors from different specialties. They … Continue reading Mesothelioma Needs a Multidisciplinary Team
Nanoparticles May Offer New Treatment for Peritoneal Mesothelioma
American scientists may have found a new way to fight mesothelioma and other cancers from the inside out by targeting cancer cells. A new article published in Biomaterials explores the use of nanoparticles. Peritoneal mesothelioma is an aggressive disease. Patients with peritoneal mesothelioma may survive several or more years after diagnosis. And there are long-term survivors. Peritoneal mesothelioma accounts for 20-25% of all mesothelioma cases. Patients with peritoneal mesothelioma have a longer life expectancy than those with other types of mesothelioma. And some studies report patients live up to 5 years after treatment. Mesothelioma is generally a “chemo-resistant” tumor. Several treatment options are available which include surgery, chemotherapy, and radiation therapy. But traditional chemotherapy often come with toxicities. New Option … Continue reading Nanoparticles May Offer New Treatment for Peritoneal Mesothelioma
A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment
A new report shows that immune checkpoint inhibitors can be a practical and rational therapeutic approach to treating mesothelioma patients. The use of ICIs to treat human tumors has quickly become part of clinical practice. Immune checkpoint inhibitors block mesothelioma’s natural resistance to immune system attack. They are among the most promising approaches to combating this intractable cancer. Researchers from the Cellular and Molecular Research Center report the use of ICIs in tumor immunotherapy. What is Tumor Immunotherapy? Malignant mesothelioma is a frustrating disease for patients and doctors. Conventional cancer treatments often do not work. If cancer recurs, doctors can try other approved treatments, even if they are not part of the official treatment guidelines. Immunotherapy is also referred to … Continue reading A Bright Future for Immune Checkpoint Inhibitors in Mesothelioma Treatment
Self-Management Activities Benefit Mesothelioma Patients
Self-management activities are a proven way to fight fatigue and anxiety. They also improve poor sleep quality. A recent report showed that self-management activities are improving lung cancer patient outcomes. Results ask mesothelioma patients to use self-management activities. They are a proven way to improve a patient’s quality of life. What are Self-Management Activities? Self-management activities allow patients to manage their disease. These activities include managing symptoms, medications, physical activity, and dietary behaviors. Results say grab a partner! Early-stage disease patients with a partner have the most benefit. Dr. Rachel Anne Rowntree from the University of Wollongong in Australia stated, “This review supports evidence that there are improved outcomes in cancer among those with a partner.” The Studies and the … Continue reading Self-Management Activities Benefit Mesothelioma Patients
Immunotherapy Drug Durvalumab Shines in Most Recent Mesothelioma Trial
Another new study confirms what Johns Hopkins researchers have been banking on – that the immunotherapy drug durvalumab can make chemotherapy more effective for mesothelioma patients. Durvalumab (IMFINZI) is an immune checkpoint inhibitor. It works by blocking the action of PD-1, a protein that mesothelioma cells use to protect themselves. Researchers theorized that deactivating PD-1 with the immunotherapy drug durvalumab might make mesothelioma tumors more responsive to chemotherapy. The latest study results, published in Nature Medicine, suggest that they were right. The findings could have implications for people around the world with inoperable malignant mesothelioma. How the Immunotherapy Drug Durvalumab Helps Fight Mesothelioma Durvalumab is one of several immune checkpoint inhibitors showing promise for mesothelioma in recent years. Keytruda (pembrolizumab) … Continue reading Immunotherapy Drug Durvalumab Shines in Most Recent Mesothelioma Trial
Study May Lead to Safer Immunotherapy for Mesothelioma
New research conducted in Europe and at Harvard University may open the door to safer immunotherapy for mesothelioma patients. Immunotherapy is one of the most promising approaches to fight malignant mesothelioma. But the potential side effects can be devastating. Now, new data suggests there are ways to reduce the complications of immunotherapy for mesothelioma. The key is to target some of the white blood cells that trigger inflammation. Inflammation is the driver behind most of the serious side effects of immunotherapy. Why Harness the Immune System? No one ever expects to contract mesothelioma. It is an extremely rare cancer. Most people who get it have spent time living or working around asbestos. Even among asbestos-exposed people, mesothelioma is rare. Scientists … Continue reading Study May Lead to Safer Immunotherapy for Mesothelioma
Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
Mesothelioma treatment delays that happened because of the COVID-19 pandemic will probably impact survival rates for some patients. A new study of Canadian lung cancer patients found that more than half of them stopped or delayed treatment because of concerns about the virus this spring. Pleural mesothelioma is a lung-related cancer. Like lung cancer patients, mesothelioma patients face a higher risk of virus-related complications because they already have breathing problems. But mesothelioma is also a fast-growing cancer. Most patients get several kinds of treatment at the same time. Mesothelioma treatment delays may give tumors a chance to grow unchecked. A Catch-22 for Mesothelioma Patients Mesothelioma patients and others with lung diseases have had to make some difficult decisions because of … Continue reading Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes
Isolated Thoracic Perfusion for Mesothelioma Symptom Relief
A new study suggests that a treatment called isolated thoracic perfusion could help alleviate some of the worst symptoms of malignant pleural mesothelioma. Isolated thoracic perfusion is a method for circulating medicine in just one area of the body. When doctors circulated chemotherapy drugs in the chests of people with pleural mesothelioma, their symptoms went away for several months. Now, the team says it is time to test the technique in a bigger pool of mesothelioma patients. The Theory Behind ITP Pleural mesothelioma is a membrane cancer that occurs in the chest. Chemotherapy drugs like Alimta can be powerful weapons against pleural mesothelioma. But they can also damage healthy tissues. When healthy tissues are damaged by chemotherapy, mesothelioma patients can … Continue reading Isolated Thoracic Perfusion for Mesothelioma Symptom Relief
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!